Karyopharm Therapeutics Inc.
KPTI
$7.46
$1.1518.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 26.37% | -1.73% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 26.37% | -1.73% | |||
| Cost of Revenue | -5.79% | 133.07% | |||
| Gross Profit | 169.28% | -104.24% | |||
| SG&A Expenses | 4.11% | 0.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.51% | 2.34% | |||
| Operating Income | 26.67% | -6.31% | |||
| Income Before Tax | -58.85% | 24.16% | |||
| Income Tax Expenses | 11.11% | 133.03% | |||
| Earnings from Continuing Operations | -58.78% | 23.78% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.78% | 23.78% | |||
| EBIT | 26.67% | -6.31% | |||
| EBITDA | 26.73% | -6.34% | |||
| EPS Basic | -56.01% | 24.48% | |||
| Normalized Basic EPS | -56.09% | 24.86% | |||
| EPS Diluted | -56.01% | 25.08% | |||
| Normalized Diluted EPS | -56.09% | 24.86% | |||
| Average Basic Shares Outstanding | 1.77% | 0.93% | |||
| Average Diluted Shares Outstanding | 1.77% | 0.93% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||